Moreover, IDH mutation would help stratify grade II/III gliomas into subgroups with distinct prognostic characteristics, therapeutic response, and clinical management (Rohle et al., 2013; Olar et al., 2015; Reuss et al., 2015; Jiang T. et al., 2016). The gene discussed is IDH1; the disease is central nervous system cancer.